Clinical trials: Tuberculosis, Pulmonary, open to volunteers
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in…
- Conditions
- Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections
- Trial name
- POSTSTAMP (NCT06262282)
- Testing
- mycobacteriophage
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Non-Tuberculous Mycobacterial (NTM) Infections
Treatment Monitoring for NTM Infections With a Symptom Diary
The primary aim of the study is to investigate the correlation between patient-reported symptoms recorded in the diary and the microbiological and radiological disease course in patients with pulmonary infections caused by…
- Trial name
- NTMdiary (NCT07131774)
- Testing
- Filling in a symptom diary
- Where
- 3 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Research Center Borstel
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
TB - Tuberculosis, HIV/AIDS
Pre- and Post-treatment Lung Microbiota, Metabolome and Immune Signatures at the Site of Disease in Patients With Active Pulmonary Tuberculosis
The diverse microbial communities in different parts of the human body (microbiome) are important for health but understudied in pulmonary tuberculosis (TB), which is the single biggest infectious cause of death in the world.
- Trial name
- TB-LUNG (NCT04700579)
- Where
- 3 sites in South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Stellenbosch
Mycobacterium Avium Complex Pulmonary Disease
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
The goal of this clinical trial is to learn if adding contezolid works to shorten the length of treatment in mycobacterium avium pulmonary disease in adults. It will also learn about the safety of extended usage of contezolid.
- Trial name
- NCT07213765
- Testing
- Contezolid, Azithromycin, Ethambutol (E)
- Where
- 6 sites in China
- Volunteers
- 188 people
- Sponsor
- Bin Cao
Tuberculosis, Pulmonary, Medication Adherence
Evaluating Urine Isoniazid Testing to Detect Nonadherence to Tuberculosis Medications in India
Tuberculosis (TB) is the leading infectious cause of death globally. India has the largest TB epidemic, accounting for one-quarter of cases and one-third of TB deaths worldwide.
- Trial name
- NCT06526221
- Testing
- Urine isoniazid testing (IsoScreen test)
- Where
- 2 sites in India
- Volunteers
- 900 people
- Sponsor
- Tufts University
Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to…
- Conditions
- Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease
- Trial name
- FORMaT-EVOLVE (NCT07485010)
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Tuberculosis in Children, Chronic Lung Disease
Paediatric Post-TB Pulmonary Rehab Study
The goal of this clinical trial is to learn if a home-based pulmonary rehabilitation program is feasible and acceptable for children ages 6-15 who have recently completed treatment for pulmonary tuberculosis.
- Conditions
- Tuberculosis in Children, Chronic Lung Disease, Post Tuberculosis
- Trial name
- PPT Rehab (NCT07097961)
- Testing
- Pulmonary Rehabilitation
- Where
- Uganda
- Volunteers
- 40 people
- Sponsor
- University of Iowa
Pulmonary Tuberculosis
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030.
- Trial name
- NCT06727864
- Testing
- 4-month regimen (2HERZ/2HRE), 6-month (2HERZ/4HRE)
- Where
- 8 sites in Taiwan
- Volunteers
- 270 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Post Pulmonary Tuberculosis, Post-Tuberculous Bronchiectasis
The Feasibility and Acceptability of a Post-tuberculosis Lung Disease Diagnostic Algorithm in Uganda.
The goal of this clinical trial is to determine whether a structured diagnostic algorithm improves the identification and referral of people with post-tuberculosis lung disease (PTLD) in primary healthcare facilities in Uganda.
- Trial name
- IMPULSE (NCT07067528)
- Testing
- A novel PTLD clinical diagnostic algorithm
- Where
- Uganda
- Volunteers
- 80 people
- Sponsor
- Mbarara University of Science and Technology
Tuberculosis, Pulmonary
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in…
- Trial name
- StatinTB (NCT04147286)
- Testing
- Atorvastatin 40mg
- Where
- South Africa
- Volunteers
- 220 people
- Sponsor
- University of Cape Town
Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
This is a multicenter, randomized, double-blind, active-controlled Phase III study to evaluate the efficacy and safety of Sudapyridine (WX-081) combined with a background regimen (BR) in patients with rifampicin-resistant…
- Trial name
- WISH (NCT05824871)
- Testing
- Sudapyridine, Bedaquiline
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis
Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis
# Brief Summary This study aims to evaluate the early bactericidal activity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible…
- Trial name
- Beams (NCT07129629)
- Testing
- Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA)
- Volunteers
- 45 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Sarcoidosis
Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis
In this study, the efficacy and safety of treating pulmonary sarcoidosis with 12 months vs. 6 months of prednisolone will be compared.
- Trial name
- DURASARC (NCT06654934)
- Testing
- Prednisolone
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Tuberculosis, Pulmonary
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
Tuberculosis (TB) remains the most important infectious disease in the world. A major barrier to tuberculosis control is poor adherence to long-term and complex treatment regimens.
- Trial name
- ORIENT (NCT05401071)
- Testing
- Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg
- Where
- 6 sites in China
- Volunteers
- 2,442 people
- Sponsor
- Huashan Hospital
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
PanACEA - STEP2C -01
This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.
- Trial name
- NCT05807399
- Testing
- BTZ-043, Rifampicin, Isoniazid
- Where
- 10 sites in Gabon, Malawi and 4 more
- Volunteers
- 390 people
- Sponsor
- Michael Hoelscher
Pulmonary TB
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease…
- Trial name
- RIFAstrat (NCT07118696)
- Testing
- Extra 600mg of Rifampicin
- Volunteers
- 1,000 people
- Sponsor
- Hamilton Health Sciences Corporation
Non-Tuberculous Mycobacteria Pulmonary Disease, Bronchiectasis
Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)
Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such…
- Trial name
- NCT07192705
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Pulmonary Tuberculosis
Ultra-Short Regimen for Elderly DS-TB
Tuberculosis (TB) remains one of the leading global public health concerns and is among the top ten causes of death from a single infectious agent.
- Trial name
- Elderly-USR (NCT07076225)
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Volunteers
- 300 people
- Sponsor
- Shenzhen Third People's Hospital
Chronic Obstructive Pulmonary Disease (COPD), TB - Tuberculosis
COPD-PTB Screening Trial in Henan, China
The goal of this trial is to evaluate the effectiveness of an active case-finding (ACF) strategy for detecting pulmonary tuberculosis (PTB) among patients with chronic obstructive pulmonary disease (COPD) in primary care settings…
- Trial name
- NCT07706972
- Testing
- ACF strategy
- Volunteers
- 25,000 people
- Sponsor
- Henan Provincial People's Hospital